

Paul Bamborough

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2145268/publications.pdf>

Version: 2024-02-01

54
papers

3,762
citations

159585
30
h-index

161849
54
g-index

54
all docs

54
docs citations

54
times ranked

4454
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery and Characterization of Small Molecule Inhibitors of the BET Family Bromodomains. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 3827-3838.	6.4	318
2	Comprehensive characterization of the Published Kinase Inhibitor Set. <i>Nature Biotechnology</i> , 2016, 34, 95-103.	17.5	289
3	Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation. <i>Science</i> , 2020, 368, 387-394.	12.6	274
4	Discovery of Epigenetic Regulator I-BET762: Lead Optimization to Afford a Clinical Candidate Inhibitor of the BET Bromodomains. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 7501-7515.	6.4	271
5	Identification of a novel series of BET family bromodomain inhibitors: Binding mode and profile of I-BET151 (GSK1210151A). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 2968-2972.	2.2	183
6	Fragment-Based Discovery of Bromodomain Inhibitors Part 1: Inhibitor Binding Modes and Implications for Lead Discovery. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 576-586.	6.4	182
7	Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 1425-1439.	6.4	177
8	Fragment-Based Discovery of Bromodomain Inhibitors Part 2: Optimization of Phenylisoxazole Sulfonamides. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 587-596.	6.4	174
9	The Discovery of I-BET726 (GSK1324726A), a Potent Tetrahydroquinoline ApoA1 Up-Regulator and Selective BET Bromodomain Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 8111-8131.	6.4	159
10	Assessment of Chemical Coverage of Kinome Space and Its Implications for Kinase Drug Discovery. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 7898-7914.	6.4	158
11	Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 4317-4334.	6.4	94
12	Structure-Based Optimization of Naphthyridones into Potent ATAD2 Bromodomain Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 6151-6178.	6.4	81
13	1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 1190-1195.	2.8	78
14	Fragment-Based Discovery of Low-Micromolar ATAD2 Bromodomain Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 5649-5673.	6.4	75
15	Discovery of a Potent, Cell Penetrant, and Selective p300/CBP-Associated Factor (PCAF)/General Control Nonderepressible 5 (GCN5) Bromodomain Chemical Probe. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 695-709.	6.4	70
16	Biphenyl amide p38 kinase inhibitors 3: Improvement of cellular and in vivo activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 4428-4432.	2.2	67
17	A Chemical Probe for the ATAD2 Bromodomain. <i>Angewandte Chemie - International Edition</i> , 2016, 55, 11382-11386.	13.8	67
18	Selectivity of Kinase Inhibitor Fragments. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 5131-5143.	6.4	65

#	ARTICLE	IF	CITATIONS
19	The discovery of 2-amino-3,5-diarylbenzamide inhibitors of IKK- $\hat{1}$ and IKK- $\hat{2}$ kinases. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 3972-3977.	2.2	60
20	Rapid and Reliable Binding Affinity Prediction of Bromodomain Inhibitors: A Computational Study. <i>Journal of Chemical Theory and Computation</i> , 2017, 13, 784-795.	5.3	59
21	GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) Proteins. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 9045-9069.	6.4	59
22	Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 4433-4437.	2.2	58
23	Discovery of a Bromodomain and Extraterminal Inhibitor with a Low Predicted Human Dose through Synergistic Use of Encoded Library Technology and Fragment Screening. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 714-746.	6.4	45
24	N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: Indazoles as phenol isosteres with improved pharmacokinetics. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 4363-4368.	2.2	44
25	p38 $\hat{1}$ Mitogen-Activated Protein Kinase Inhibitors: Optimization of a Series of Biphenylamides to Give a Molecule Suitable for Clinical Progression. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 6257-6269.	6.4	41
26	The Optimization of a Novel, Weak Bromo and Extra Terminal Domain (BET) Bromodomain Fragment Ligand to a Potent and Selective Second Bromodomain (BD2) Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 9093-9126.	6.4	41
27	Design and Synthesis of a Highly Selective and <i>In Vivo</i> -Capable Inhibitor of the Second Bromodomain of the Bromodomain and Extra Terminal Domain Family of Proteins. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 9070-9092.	6.4	40
28	Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 9020-9044.	6.4	38
29	Biphenyl amide p38 kinase inhibitors 1: Discovery and binding mode. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 318-323.	2.2	36
30	System-based drug discovery within the human kinome. <i>Expert Opinion on Drug Discovery</i> , 2012, 7, 1053-1070.	5.0	32
31	Naphthyridines as Novel BET Family Bromodomain Inhibitors. <i>ChemMedChem</i> , 2014, 9, 580-589.	3.2	32
32	Biphenyl amide p38 kinase inhibitors 2: Optimisation and SAR. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 324-328.	2.2	28
33	4-Phenyl-7-azaindoles as potent and selective IKK2 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 2504-2508.	2.2	28
34	GSK973 Is an Inhibitor of the Second Bromodomains (BD2s) of the Bromodomain and Extra-Terminal (BET) Family. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 1581-1587.	2.8	25
35	Progress Towards the Development of Anti-Inflammatory Inhibitors of IKKβ. <i>Current Topics in Medicinal Chemistry</i> , 2009, 9, 623-639.	2.1	24
36	Kinase array design, back to front: Biaryl amides. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 5285-5289.	2.2	22

#	ARTICLE	IF	CITATIONS
37	4-Phenyl-7-azaindoles as potent, selective and bioavailable IKK2 inhibitors demonstrating good in vivo efficacy. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 5222-5226.	2.2	22
38	Application of Atypical Acetyl-lysine Methyl Mimetics in the Development of Selective Inhibitors of the Bromodomain-Containing Protein 7 (BRD7)/Bromodomain-Containing Protein 9 (BRD9) Bromodomains. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 5816-5840.	6.4	21
39	Expanding Bromodomain Targeting into Neglected Parasitic Diseases. <i>ACS Infectious Diseases</i> , 2021, 7, 2953-2958.	3.8	20
40	A Qualified Success: Discovery of a New Series of ATAD2 Bromodomain Inhibitors with a Novel Binding Mode Using High-Throughput Screening and Hit Qualification. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 7506-7525.	6.4	19
41	Template-Hopping Approach Leads to Potent, Selective, and Highly Soluble Bromo and Extraterminal Domain (BET) Second Bromodomain (BD2) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 3249-3281.	6.4	19
42	Targeting IKKbeta for the treatment of rheumatoid arthritis. <i>Drug News and Perspectives</i> , 2010, 23, 483.	1.5	19
43	3,5-Disubstituted-indole-7-carboxamides: The discovery of a novel series of potent, selective inhibitors of IKK- β . <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 2255-2258.	2.2	18
44	Fragments in bromodomain drug discovery. <i>MedChemComm</i> , 2015, 6, 1587-1604.	3.4	17
45	Aiming to Miss a Moving Target: Bromo and Extra Terminal Domain (BET) Selectivity in Constrained ATAD2 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 8321-8336.	6.4	17
46	Fragment-based Scaffold Hopping: Identification of Potent, Selective, and Highly Soluble Bromo and Extra Terminal Domain (BET) Second Bromodomain (BD2) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 10772-10805.	6.4	17
47	Optimization of Potent ATAD2 and CECR2 Bromodomain Inhibitors with an Atypical Binding Mode. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 5212-5241.	6.4	14
48	Design, Synthesis, and Characterization of I-BET567, a Pan-Bromodomain and Extra Terminal (BET) Bromodomain Oral Candidate. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2262-2287.	6.4	14
49	The discovery and initial optimisation of pyrrole-2-carboxamides as inhibitors of p38 β MAP kinase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 3936-3940.	2.2	12
50	CDK12 inhibition reduces abnormalities in cells from patients with myotonic dystrophy and in a mouse model. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	12
51	A Chemical Probe for the ATAD2 Bromodomain. <i>Angewandte Chemie</i> , 2016, 128, 11554-11558.	2.0	10
52	3,5-Disubstituted-indole-7-carboxamides as IKK β Inhibitors: Optimization of Oral Activity via the C3 Substituent. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 1164-1169.	2.8	7
53	Investigation of Janus Kinase (JAK) Inhibitors for Lung Delivery and the Importance of Aldehyde Oxidase Metabolism. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 633-664.	6.4	6
54	Optimization of Naphthyridones into Selective TATA-Binding Protein Associated Factor 1 (TAF1) Bromodomain Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 1308-1317.	2.8	4